← board
SCLXW
distress 4/10 · elevated risk$0.20+48%today-4% from 52w high
Revenue
pre-revenue
Liquidity
$3M
Runway
1.0 yrs
Shares 1y
+22%
Price & events
+34.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+47.8%
1D
-4.3%
1W
+47.8%
1M
+47.8%
3M
—
6M
—
1Y
—
2Y
—
5Y
+34.9%
All
Overview
- Market Cap
- $1.71M
- Volume
- 6.50K
- 52 Week Range
- $0.12 – $0.21
- Total Shares
- 8.49M
- Float Shares
- 5.69M
- RVOL
- 7.57x
- Beta
- 1.73
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- 2025-11-25partnershipCompleted second tranche investment in Datavault AI, including purchase of pre-funded warrant and license agreement for intellectual property.SEC 8-K
- 2025-11-03partnershipScilex licenses Datavault AI's AI-driven tech for tokenization and monetization of biotech assets.SEC 8-K
- 2025-09-25partnershipScilex enters securities purchase agreement to invest $150M in Bitcoin in Datavault AI for 15M shares and pre-funded warrant for 263,914,094 shares.SEC 8-K
- 2025-09-23partnershipSecurities purchase agreement with Biconomy to sell Semnur shares for Bitcoin and collaborate on crypto strategies.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.